Back
Efficacy of JAK inhibitors in Crohn's Disease.
Journal article

Efficacy of JAK inhibitors in Crohn's Disease.

  • Rogler G Department of Gastroenterology & Hepatology, University Hospital of Zürich, Switzerland.
  • 2019-11-30
Published in:
  • Journal of Crohn's & colitis. - 2020
Crohn’s disease
Janus Kinase Inhibitors
clinical trials
induction of remission
maintenance of remission
side effects
treatment
English Inhibition of Janus kinases [JAKs] in Crohn's disease [CD] patients has shown conflicting results in clinical trials. Tofacitinib, a pan-JAK inhibitor, showed efficacy in ulcerative colitis [UC] and has been approved for the treatment of patients with moderate to severe UC. In contrast, studies in CD patients were disappointing and the primary end point of clinical remission could not be met in the respective phase II induction and maintenance trials. Subsequently, the clinical development of tofacitinib was discontinued in CD. In contrast, efficacy of filgotinib, a selective JAK1 inhibitor, in CD patients was demonstrated in the randomized, double-blinded, placebo-controlled phase II FITZROY study. Upadacitinib also showed promising results in a phase II trial in moderate to severe CD. Subsequently, phase III programmes in CD have been initiated for both substances, which are still ongoing. Several newer molecules of this class of orally administrated immunosuppressants are being tested in clinical programmes. The concern of side effects of systemic JAK inhibition is addressed by either exclusively intestinal action or higher selectivity [Tyk2 inhibitors]. In general, JAK inhibitors constitute a new promising class of drugs for the treatment of CD.
Language
  • English
Open access status
hybrid
Identifiers
Persistent URL
https://sonar.ch/global/documents/151396
Statistics
Document views: 31 File downloads: